Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.Glucagon-like peptide-1 receptor agonists gained approval as drugs to treat diabetes and obesity starting in the 2000s.
The GLP-1 receptor agonists used clinically are based on exendin-4 and native GLP-1 and are available as formulations for daily or weekly s.c. or oral administration.Liraglutide was therefore the first long-acting GLP-1 receptor agonist with continuous efficacy over a 24 h period.
Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance.To circumvent this, we developed a long-lasting GLP-1 receptor agonist by the fusion of GLP-1 with human IgG2 Fc (GLP-1/hIgG2).
As we can see from the illustration, Long-Acting Glp-1 Receptor Agonist Formulations has many fascinating aspects to explore.
First page of Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes PDF Icon.At present, the GLP-1 receptor agonists need to be administered once or twice daily. Several once-weekly GLP-1 receptor agonists are in phase 3 development.
Long acting agonists include liraglutide (once daily), and exenatide once weekly (ow), albiglutide, dulaglutide and semaglutide which, except for liraglutide, are intended for weekly s.c. administration.The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) medications have been shown to be effective in achieving optimal glucose control and reducing all-cause death, cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, and...
